Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qibei Jiedu Formula for Acute Radiation Dermatitis in Breast Cancer
NCT07380230Not yet recruiting
- Sponsor
- Lifeng Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Qibei Jiedu Formula in acute radiation dermatitis (2 arms), sponsored by Lifeng Pharmaceutical. Primary endpoint: Incidence of Grade >=2 Acute Radiation Dermatitis at Day 49. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Qibei Jiedu Formula
03
Conditions
acute radiation dermatitis
Beyond the preview
Go deeper on NCT07380230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07380230.